Goldman Sachs Maintains Buy on Codiak BioSciences, Lowers Price Target to $8
Goldman Sachs maintains Codiak BioSciences (NASDAQ:CDAK) with a Buy and lowers the price target from $18 to $8.
Codiak BioSciences’s Pan Beta-Coronavirus Vaccine Shows Encouraging Action In Animal Studies
Codiak BioSciences Inc (NASDAQ:CDAK) announced new preclinical data from its pan beta-coronavirus vaccine program. The data demonstrate the potential for the…
Looking Into Codiak BioSciences’s Return On Capital Employed
According to Benzinga Pro, during Q4, Codiak BioSciences (NASDAQ:CDAK) earned $16.66 million, a 176.78% increase from the preceding quarter. Codiak BioSciences also posted a total of $7.70 million in sales, a 565.25% increase since Q3.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Wedbush Maintains Outperform on Codiak BioSciences, Lowers Price Target to $24
Wedbush analyst David Nierengarten maintains Codiak BioSciences (NASDAQ:CDAK) with a Outperform and lowers the price target from $34 to $24.
Codiak BioSciences Highlights Preclinical Data For exoASO-STAT6 Program As Treatment For Primary, Metastatic Hepatic Cancers
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models –
– Phase 1 study expected to begin in 1H 2022 –
CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) --